1. Home
  2. DGII vs ANAB Comparison

DGII vs ANAB Comparison

Compare DGII & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digi International Inc.

DGII

Digi International Inc.

HOLD

Current Price

$42.52

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$44.34

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGII
ANAB
Founded
1985
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
DGII
ANAB
Price
$42.52
$44.34
Analyst Decision
Strong Buy
Buy
Analyst Count
5
12
Target Price
$48.80
$58.09
AVG Volume (30 Days)
300.2K
431.3K
Earning Date
02-04-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
77.05
N/A
EPS
1.08
N/A
Revenue
$430,221,000.00
$169,467,000.00
Revenue This Year
$10.51
$135.45
Revenue Next Year
$8.01
N/A
P/E Ratio
$39.67
N/A
Revenue Growth
1.46
196.42
52 Week Low
$22.39
$12.21
52 Week High
$48.00
$52.47

Technical Indicators

Market Signals
Indicator
DGII
ANAB
Relative Strength Index (RSI) 45.36 48.56
Support Level $42.48 $42.00
Resistance Level $45.13 $47.36
Average True Range (ATR) 1.21 2.35
MACD -0.39 -0.92
Stochastic Oscillator 8.14 25.12

Price Performance

Historical Comparison
DGII
ANAB

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: